Latest News

Oslo, Norway, July 16, 2018: Photocure ASA (PHO:OSE) announced that the Patient Reported Outcomes (PRO) with Blue Light Cystoscopy (BLC™) with Cysview® Study was published online, in the prestigious British Journal of Urology, International: https://doi.org/10.1111/bju.14481

Oslo, Norway, 26 June 2018: Photocure ASA (OSE: PHO), announces today that President and Chief Executive Officer, Kjetil Hestdal, will step down effective 1 July 2018 as the company is entering a new growth phase with focus on global commercial development. The Board of Directors has initiated a search for his replacement and Chief Financial
Officer Erik Dahl is appointed as interim CEO. Mr. Hestdal will be available to the company until 30 December 2018.

Oslo, Norway, May 31, 2018: Photocure ASA (PHO:OSE) announced today that results from the Blue Light Cystoscopy (BLC™) with Cysview^® Registry Study was published on-line, in the prestigious official journal of the Society of Urological Oncology. Data from the publication showed that BLC significantly increases detection rates of flat, aggressive Carcinoma in Situ lesions (CIS) and papillary lesions compared to WLC alone and can result in upstaging or upgrading in about 14% of patients and that repeat use is safe.

Oslo, Norway, 23 May 2018: Photocure ASA (OSE:PHO), today reported a revenue growth of 36% in local currency for the important U.S. market in the first quarter of 2018, contributing to Hexvix/Cysview revenues of NOK 40.7 million (Q1 2017: NOK 36.5) and a recurring EBITDA of NOK -4.3 million (NOK -4.0 million). With the reimbursement of Blue Light Cystoscopy with Cysview, FDA approval of label expansion for Cysview and the launch of Cysview in combination with flexible cystoscopes in the surveillance of bladder cancer patients, the company expects a continued solid growth towards the 2020 ambitions.

Photocure will present its first quarter 2018 report on Wednesday 23 May 2018 at Hotel Continental, Oslo, Norway.

Oslo, Norway, Photocure ASA (OSE: PHO), May 16, 2018, announced today the launch of Blue Light Cystoscopy (BLC™) with Cysview for a new indication of surveillance cystoscopy of bladder cancer.

Oslo, Norway, May 14th, 2018: Photocure ASA (PHO:OSE) announced today that Photocure will be exhibiting Blue Light Cystoscopy (BLC™) with Cysview in Booth 1825, during the American Urological Association Meeting (AUA 2018) in San Francisco, CA.

Oslo, Norway, 9 May 2018: Photocure ASA (OSE: PHO), held its annual general meeting on 9 May 2018 at 17:00 hours (CET).

Your integrity is important to us in Photocure. Therefore, we update our Privacy Policy and Terms of Use so that you understand how we collect and use your information.

You receive this email because you are a subscriber to our news.

If you no longer wish to receive the news from us, please click on the unsubscribe link below.

Princeton, New Jersey, May 3, 2018: Photocure ASA (OSE: PHO) is pleased to announce that Photocure will be presenting at the J.P. Morgan - Bio New Jersey Bio-Partnering meeting conference. The presentation will be held by Ambaw Bellete, President, Photocure Inc.

Oslo, 16 April 2018: Photocure ASA (OSE: PHO), calls for the annual general meeting of PHO to be held at Hoffsveien 4, 1st floor, 0275 Oslo, Norway on 9th May 2018 at 17:00 hours (CET).

Oslo, Norway, April 3rd, 2018, Photocure ASA (OSE: PHO), is pleased to announce that a new study on Blue Light Cystoscopy (BLC™) with Hexvix® using the KARL STORZ flexible videoscope system in the outpatient setting for the laser treatment of Low-Grade bladder tumors was published in Scandinavian Journal of Urology.

Oslo, Norway, March 20, 2018: Photocure ASA (OSE: PHO), is pleased to announce that Blue Light Cystoscopy (BLCTM) with Hexvix® was featured during the EAU annual meeting held in Copenhagen, Denmark, March 16th – 20th. The EAU is one of the largest international meetings in urology, attended by more than 12,000 urologists and exhibitors from over 110 countries.

Oslo, Norway, 27 February 2018: Photocure ASA (OSE:PHO), today reported a revenue growth of 27% for the important U.S. market in the fourth quarter of 2017, contributing to Hexvix®/Cysview® revenues of NOK 39.4 million (Q4 2016: NOK 31.6) and an EBITDA of NOK 0.9 million for the commercial franchise. With the reimbursement of Blue Light Cystoscopy with Cysview for Medicare patients and FDA approval of label expansion for Cysview, the company expects a continued solid growth towards the 2020 ambitions.

Photocure will present its fourth quarter and full year 2017 report on Tuesday 27 February 2018 at Hotel Continental, Oslo, Norway.

Oslo, Norway, February 16, 2018 Photocure ASA (OSE: PHO), announced today that the U.S. Food and Drug Administration (FDA) approved its supplemental new drug application (sNDA) to extend the indication for Blue Light Cystoscopy (BLC™) with Cysview® to include Flexible Cystoscopes, which are used in the ongoing surveillance of patients with bladder cancer. This is the only combination of drug and device approved for the detection of bladder cancer.

BLC with Cysview featured in Urology Time article January 26, 2018: “Role of blue light cystoscopy to detect bladder cancer”. Increased tumor detection, reduced recurrence/progression support its use in NMIBC patients.

Oslo, Norway, December 13, 2017 - Photocure ASA (OSE: PHO) announces today that the company will present at the DNB Nordic Healthcare Conference on 14th of December 2017 in Oslo, Norway.